NCT00096304终止1 期
Phase I Trial of Epirubicin and Taxotere in Patients With Metastatic Androgen Independent Prostate Cancer
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 36
- 试验地点
- 2
研究概览
简要总结
RATIONALE: Drugs used in chemotherapy, such as epirubicin and docetaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of epirubicin when given with docetaxel in treating patients with metastatic prostate cancer.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 120 Years（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (2)
Loading locations...
相似试验
Unknown
2 期
Docetaxel and Epirubicin as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Adenocarcinoma of the StomachGastric CancerNCT00075465GERCOR - Multidisciplinary Oncology Cooperative Group
已完成
1 期
Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast CancerBreast CancerNCT00066443NCIC Clinical Trials Group93
已完成
1 期
Docetaxel and Epirubicin With and Without G-CSF in Treating Women With Metastatic Breast CancerNeutropeniaBreast CancerNCT00002866NCIC Clinical Trials Group50
已完成
2 期
Gemcitabine and Docetaxel in Treating Patients With Recurrent Stage III or Stage IV Non-Small Cell Lung CancerLung CancerNCT00278460Wake Forest University Health Sciences49
已完成
2 期
Epirubicin, Docetaxel, and Capecitabine in Treating Women With Stage IIIA or Stage IIIB Breast CancerBreast CancerNCT00645866Mayo Clinic47